Tuberculosis, Multidrug-Resistant
"Tuberculosis, Multidrug-Resistant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
Descriptor ID |
D018088
|
MeSH Number(s) |
C01.252.410.040.552.846.775
|
Concept/Terms |
Tuberculosis, Multidrug-Resistant- Tuberculosis, Multidrug-Resistant
- Multidrug-Resistant Tuberculosis
- Tuberculosis, Multidrug Resistant
- Tuberculosis, MDR
- MDR Tuberculosis
- Tuberculosis, Multi-Drug Resistant
- Multi-Drug Resistant Tuberculosis
- Tuberculosis, Multi Drug Resistant
|
Below are MeSH descriptors whose meaning is more general than "Tuberculosis, Multidrug-Resistant".
Below are MeSH descriptors whose meaning is more specific than "Tuberculosis, Multidrug-Resistant".
This graph shows the total number of publications written about "Tuberculosis, Multidrug-Resistant" by people in this website by year, and whether "Tuberculosis, Multidrug-Resistant" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 1 | 2 |
1997 | 2 | 0 | 2 |
1998 | 1 | 0 | 1 |
2001 | 0 | 1 | 1 |
2004 | 3 | 0 | 3 |
2005 | 1 | 0 | 1 |
2006 | 0 | 1 | 1 |
2008 | 1 | 0 | 1 |
2009 | 0 | 1 | 1 |
2010 | 1 | 0 | 1 |
2011 | 1 | 0 | 1 |
2012 | 1 | 0 | 1 |
2013 | 1 | 0 | 1 |
2014 | 4 | 2 | 6 |
2015 | 4 | 1 | 5 |
2016 | 7 | 1 | 8 |
2017 | 8 | 5 | 13 |
2018 | 14 | 0 | 14 |
2019 | 7 | 1 | 8 |
2020 | 10 | 1 | 11 |
2021 | 4 | 0 | 4 |
2022 | 9 | 0 | 9 |
2023 | 9 | 0 | 9 |
2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tuberculosis, Multidrug-Resistant" by people in Profiles.
-
Multidrug-resistant tuberculosis. Nat Rev Dis Primers. 2024 Mar 24; 10(1):22.
-
Tuberculosis in people of Ukrainian origin in the European Union and the European Economic Area, 2019 to 2022. Euro Surveill. 2024 Mar; 29(12).
-
Anti-Tuberculosis Potential of OJT008 against Active and Multi-Drug-Resistant Mycobacterium Tuberculosis: In Silico and In Vitro Inhibition of Methionine Aminopeptidase. Int J Mol Sci. 2023 Dec 05; 24(24).
-
[Treatment of MDR, pre-XDR, XDR and rifampicin resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment dated 19.09.2023 to the Sk2-Guideline: Tuberculosis in adulthood of the German Central Committee against Tuberculosis (DZK) on behalf of the German Respiratory Society (DGP)]. Pneumologie. 2024 Jan; 78(1):35-46.
-
Impact of Mycobacterium tuberculosis strain type on multidrug-resistant tuberculosis severity, Republic of Moldova. J Infect. 2023 Dec; 87(6):588-591.
-
Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis. Am J Respir Crit Care Med. 2023 07 15; 208(2):130-131.
-
[Treatment of tuberculosis: what is new?] Inn Med (Heidelb). 2023 Jul; 64(7):701-707.
-
Limited Nosocomial Transmission of Drug-Resistant Tuberculosis, Moldova. Emerg Infect Dis. 2023 05; 29(5):1046-1050.
-
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infect Dis. 2023 04; 23(4):e122-e137.
-
Long-term treatment outcomes in patients with multidrug-resistant tuberculosis. Clin Microbiol Infect. 2023 Jun; 29(6):751-757.